Controlled drug release for inflammatory bowel disease (IBD)

Area of Science:

• Pharmaceutical Sciences
• Drug Delivery Systems
• Polymer Science

Background:

• Controlled drug release is crucial for effective therapeutic outcomes.
• Crohn's disease requires targeted drug delivery to the ileocecal region for optimal management.
• Super-disintegrants like crospovidone and pH-dependent polymers such as Eudragit L30D are key components in advanced drug formulations.

Purpose of the Study:

• To design and evaluate a novel pulsatile drug delivery system for ileocecal targeting.
• To investigate the role of crospovidone and Eudragit L30D in achieving controlled, pH-dependent drug release.
• To assess the pre-formulation interactions between drug and polymer for formulation optimization.

Main Methods:

• Utilizing crospovidone as a super-disintegrant for immediate release post-lag time.
• Employing Eudragit L30D, a pH-dependent polymer, to ensure drug release after a 4-5 hour lag time.
• Conducting pre-formulation studies to analyze drug-polymer interactions.
• Optimizing formulation batches and evaluating the correlation between predicted and actual drug release values.

Main Results:

• The formulation demonstrated a lag time of 4-5 hours, characteristic of Eudragit L30D's pH-dependent properties.
• Pre-formulation studies confirmed essential drug-polymer interactions for successful formulation.
• Optimization batches showed a high correlation coefficient (r-value), indicating a strong linear relationship between predicted and actual values.
• The developed system achieved controlled drug release, meeting the criteria for pulsatile delivery.

Conclusions:

• The designed pulsatile drug delivery system shows significant promise for ileocecal targeting.
• This formulation is a viable candidate for Crohn's disease management, offering targeted and controlled drug release.
• The study highlights the successful integration of super-disintegrants and pH-dependent polymers for advanced drug delivery applications.